Type 2 Diabetes Drugs Lawsuit

Free Case Evaluation

Injury caused by antidiabetic medications can result in a need for expensive medical treatments and hospitalizations.  They can also require the need for long-term treatments, result in permanent disability and may even result in death.

The SGLT2 inhibitors are the newest class of antidiabetics used for Type 2 diabetes, but after only two years of use, have already been shown responsible for a number of serious adverse events including at least 20 cases of Diabetic Ketoacidosis, a life-threatening condition.  A Japanese report also indicates that at least 10 patients may have died due to use of the SGLT2 medications.

Farxiga and Invokana Lawsuits

The class of antidiabetic medications known as type 2 sodium-glucose co-transporter (SGLT2) inhibitors include the medications:

In the recent past, thousands of lawsuits have been filed and settled for newer antidiabetic medications which have caused medical injury.  These patients may be eligible for compensation for those medical costs, lost wages and pain and suffering caused by the medication.  Families whose loved ones have died after using antidiabetic medications may be eligible for wrongful death compensation.

It is not yet known how many type 2 diabetic patients have been or may be injured by the SGLT2 inhibitors but data indicates that thousands of serious adverse events, including diabetic ketoacidosis, may be expected.  Other antidiabetic lawsuits have been filed for claims such as:

  • Manufacture and marketing of a defective or dangerous drug
  • Failure to adequately warn the public and health care profession about drug risks
  • Concealment of known drug risks
  • Improper or illegal marketing activities

Each suspected occurrence of medical injury that may be related to the use of a drug must be considered independently.  The circumstances for each case are different from others, but in other antidiabetic cases, patients or family members have been successful at receiving compensation for damages.  Despite a history of success for thousands of patients, there is no guarantee of a settlement award as each case is unique and must be evaluated by an experienced attorney.

SGLT2 Warnings

The first SGLT2 medication to be consider for approval was Farxiga.  The Food and Drug Administration (FDA) initially denied the application in 2012, due to concerns about the drug’s effects on the liver.  In March of 2013, Invokana was approved but five out of the 15 advisory panel members had voted against approval due to a potential for increased heart attack.

After additional study, Farxiga was approved in January of 2014 and the last member of the class, followed in August of 2014 even though reports of serious adverse events including diabetic ketoacidosis had already been received by the FDA.

Prior to Invokana’s approval, a consumer advocacy group, Public Citizen had expressed extreme objection to the new medications, stating that adequate safety information was not available and that the situation was concerning as other “new” antidiabetic classes had been shown to cause serious harm.  Public Citizen has placed members of the SGLT2 class on its “Do Not Use” website list.

The same group has also objected to marketing used for the SGLT2 inhibitors which state “advantages” of the drug including “reduced blood pressure” and the possibility of weight loss.  Public Citizen has stated that “hypotension” (low blood pressure) is a listed side effect and not a benefit and that advertising a weight loss potential close to the “approved use” of the treatment of Type 2 diabetes may lead some to believe the medication is for weight loss.

The FDA issued a warning notification to health care professionals in May 2015, regarding the diabetic ketoacidosis risk.  This letter cited the 20 ketoacidosis reports the agency received but IMS, a healthcare data collection company, has identified hundreds of additional serious adverse events that may have occurred due to Invokana, Farxiga.

None of the literature originally included diabetic ketoacidosis as a serious risk of the medications.  Hundreds of thousands of prescriptions are filled for Invokana, Farxiga and each month.

Diabetic Ketoacidosis

Diabetic ketoacidosis is caused by the body’s inability to use glucose as energy.  When the cells cannot obtain enough glucose, fat stores must be used.  Ketones, a highly acidic by product of fat metabolism, build up in the bloodstream, creating a dangerous medical condition which can quickly become life-threatening.

Unfortunately, most Type 2 diabetics have never experienced ketosis and will not easily recognize the symptoms.  Any symptom of Diabetic Ketosis warrants immediate medical attention.

Symptoms of diabetic Ketoacidosis can include:

  • Excessive thirst and hunger
  • Excessive urination
  • Gastrointestinal disturbance including pain and nausea
  • Weakness, Fatigue and Dizziness
  • Irritability, Sweating and Rapid Heartbeat
  • Shortness of Breath with “Fruity” odor

If the condition is not treated immediately, symptoms may become worse including:

  • Vomiting
  • Confusion and extreme irritability
  • Dizziness and fainting
  • Difficulty Breathing
  • Unconsciousness

If left untreated, the brain may swell and the condition will become life-threatening.

About Type 2 Diabetes and Treatments

Type 2 Diabetes is a disease that affects over 28 million Americans.  Type 2 diabetics lack the ability to correctly move sugar or glucose from the blood stream where it can be used as energy.  This is because the insulin that is required to help move the glucose is either deficient in amount or the body has become resistant to it.

Over time, high glucose levels in the blood may cause permanent damage including blindness, kidney failure and the need for amputation as the blood system is destroyed by sugar.  Type 2 diabetes may also contribute to cardiovascular disease and other medical conditions.

Most antidiabetic medications work by increasing the body’s supply of insulin or by making the cells more sensitive to it.  The newer SGLT2 inhibitors, sometimes called “gliflozins” due to the generic names (canagliflozin, dapagliflozin, and empagliflozin), work differently and were designed to help patients who did not respond adequately to other medications.

SGLT2 inhibitors block a chemical (SGLT2) which allows the kidneys to reabsorb normally secreted glucose back into the bloodstream so that it may be conserved.  If the SGLT2 enzyme is blocked, the extra sugar will be excreted in the urine, lowering the blood sugar.  Unfortunately, some patients taking Invokana or Farxiga.

Side Effects

Every medication may cause side effects.  Most of the SGLT2 inhibitor side effects are mild to moderate but others may be more severe.

Common side effects may include:

  • Yeast infections of the genital area in both men and women
  • Urinary tract infections
  • Photosensitivity reactions (sun intolerance)
  • Rash
  • Loss of energy

More severe side effects may include:

  • Hypotension (low blood pressure)
  • Laboratory value changes (high potassium cholesterol, hemoglobin)
  • Decreases in kidney function
  • Other allergic reactions

Some of these effects may be medically important and may warrant medical treatment.  Manufacturers of the medications have also been ordered by the FDA to conduct additional safety studies to examine effects on the heart, bones, liver, and the risk of cancer and pregnancy effects.

 

View Sources

  1. American Diabetes Association, (2015) Living with Diabetes, Complications: Ketoacidosis, ADA Diabetes.org, Accessed on 08 June 2015 http://www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html
  2. American Diabetes Association, (10 June 2014), Statistics About Diabetes, ADA Diabetes.org, Accessed on 08 June 2015 http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav
  3. AstraZeneca and Bristol-Myers Squibb, (13 January 2014), US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes, AstraZeneca, Accessed on 08 June 2015 http://www.astrazeneca.com/Media/Press-releases/Article/13012014–us-fda-approves-farxiga-dapagliflozin
  4. Berkot, B., (15 May 2015), FDA warns on newer class of type 2 diabetes drugs, Reuters, Accessed on 08 June 2015 http://www.reuters.com/article/2015/05/15/us-fda-diabetes-idUSKBN0O01P520150515
  5. Brooks, M., (15 May 2015), SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA, Medscape Pharmacists, Accessed on 08 June 2015 http://www.medscape.com/viewarticle/844754
  6. FDA prescribing information, Farxiga Prescribing Information, Drugs.com, Accessed on 08 June 2015 http://www.drugs.com/pro/farxiga.html
  7. FDA prescribing information, Invokana Prescribing Information, Drugs.com, Accessed on 08 June 2015 http://www.drugs.com/pro/invokana.html
  8. Fiore, K., SGLT2 Inhibitors May Up Glucose Production, MedPage Today, Accessed on 08 June 2015 http://www.medpagetoday.com/Endocrinology/Diabetes/44014
  9. Food and Drug Administration (15 May 2015), FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, U.S. Food and Drug Administration, Accessed on 08 June 2015 http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
  10. Hahn, P., (19 August 2014), Part 2: “IT’S A NIGHTMARE”: After the Avandia debacle, is history about to repeat itself?, Canada Free Press, Accessed on 08 June 2015 http://canadafreepress.com/index.php/article/65394
  11. Huston, L., (29 March 2013), FDA Approves First SGLT2 Inhibitor For Diabetes, Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/larryhusten/2013/03/29/fda-approves-first-sglt2-inhibitor-for-diabetes/
  12. Janssen Pharmaceutica (26 May 2014) First-in-Class Type 2 Diabetes Medication Approved in Canada – INVOKANA offers a new approach to treatment, Janssen.ca, Accessed on 08 June 2015 http://www.janssen.ca/subcategory_docdownload?id=sites/default/files/about_us_media/INVOKANA%20Launch%20News%20Release%20FINAL.pdf
  13. LaMattina, J., (13 April 2015), Should the FDA Require CV Outcome Studies for Diabetes Drugs Before Approval? Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/johnlamattina/2015/04/13/should-the-fda-require-cv-out come-studies-for-diabetes-drugs-before-approval/
  14. MacDonald, E., (01 April 2015), FDA Urged to Fine Drugmakers Over Ads, FoxBusiness, Accessed on 08 June 2015 http://www.foxbusiness.com/economy-policy/2015/04/01/fda-urged-to-fine-drugmakers-over-ads/
  15. Mayo Clinic Staff, (24 July 2014), Type 2 diabetes, Treatments and drugs, Mayo Clinic, Accessed on 08 June 2015 http://www.mayoclinic.org/diseases-conditions/type-2-diabetes/basics/treatment/con-20031902
  16. Public Citizen, (10 January 2013), FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee, Public Citizen, Accesse on 08 June 2015 http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=3793
  17. Rodale, M., (06 April 2014), The Worst New Drug of 2014, Huffington Post, Accessed on 08 June 2015 http://www.huffingtonpost.com/maria-rodale/the-worst-new-drug-of-201_b_4723514.html
  18. Sun, L., (15 January 2014), 3 ways Johnson & Johnson is Revolutionizing Diabetes, Motley Fool, Accessed on 08 June 2015 http://www.fool.com/investing/general/2014/01/15/3-ways-johnson-johnson-is-revolutionizing-diabetes.aspx
  19. Tauchi, K., Accessed on 08 June 2015, 10 deaths reported following use of newly marketed diabetes drugs, The Asahi Shimbun, Accessed on 08 June 2015 http://ajw.asahi.com/article/behind_news/social_affairs/AJ201501090058
  20. Team, T., (20 May 2015), FDA’s New Warning About Invokana May Not Matter Much For J&J; Let’s Focus On Pipeline Instead, Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/greatspeculations/2015/05/20/fdas-new-warning-about-invokana-may-not-matter-much-for-jj-lets-focus-on-pipeline-instead/
  21. Thomas, K., FDA Advisory Panel Votes to Approve Diabetes Drug, New York Times, Accessed on 08 June 2015 http://www.nytimes.com/2013/01/11/business/fda-advisory-panel-votes-to-approve-diabetes-drug.html?partner=rss&emc=rss&_r=0
Have you been affected by a drug or device listed? Call 1-888-537-3057